Andrew S. Morgenstern, OD, FAAO, FNAP

Andrew Morgenstern, OD, FAAO, FNAP, gives a brief history of the International Keratoconus Academy of Eye Care Professionals.

The goal of the inaugural International Keratoconus Academy (IKA) Keratoconus Symposium in Scottsdale, Arizona, was to help preserve vision.

President and CEO of the International Keratoconus Academy Andrew Morgenstern, OD, FAAO, FNAP, shares some snippets about the live white paper development session and the patient Q&A happening at the inaugural IKA Keratoconus Symposium.

Over the years, IKA has become an invaluable resource for eye care professionals.

Expert eye care specialists comment on the use of aceclidine as a selective miotic for the treatment of presbyopia.

Andrew S. Morgenstern discusses the selectivity of miotic agents in isolating the pupil while limiting adverse events for the management of presbyopia.

Francis S. Mah, MD, reviews miotic agents that are available or under investigation for the treatment of presbyopia.

Andrew S. Morgenstern, OD, FAAO, FNAP, highlights the importance of reducing pupil size to a certain level to optimize near vision for patients with presbyopia.

Expert eye care specialists discuss the role of miotic agents in targeting presbyopia in patients.

Drs Andrew S. Morgenstern and Francis S. Mah provide insight on the functionality of ocular accommodation as an autofocus lens and how this is affected in patients with presbyopia.

Francis S. Mah, MD, and Andrew S. Morgenstern, OD, FAAO, FNAP, review the impact of presbyopia on quality of life as well as current treatment options and unmet needs for disease management.

Andrew Morgenstern, OD, FAAO, sits down to talk myopia in children and adults, how to treat it, and how to go prevent it at the American Optometric Association’s Optometry’s Meeting in Washington, DC.

After much anticipation and a long wait for both clinicians and patients in need, the U.S. Food and Drug Administration (FDA) approved corneal cross-linking (CXL) in mid April. This procedure is globally considered the only method of halting the progressive family of diseases called corneal ectasias, including keratoconus.

In a landmark paper titled “Global consensus on keratoconus and ectatic diseases” published in the April 2015 issue of Cornea, Gomes et al sought to reach a consensus of the definition, concepts, clinical management, and surgical treatments of keratoconus and the family of corneal ectatic diseases.